We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Gastroenterology

Adherence to Surveillance in the Watch and Wait Approach for Rectal Cancer

MedXY Editorial Team•May 8, 2026•Gastroenterology
cancer surveillanceNonoperative Managementoncologyrectal cancerWatch and Wait

Understanding the Watch and Wait Approach

For patients with locally advanced rectal cancer who achieve complete clinical response after neoadjuvant therapy, the Watch and Wait strategy offers a promising alternative to invasive surgery. This approach replaces surgical resection with rigorous surveillance protocols designed to detect cancer regrowth early while preserving bowel function. Rather than removing the rectum immediately, patients undergo regular monitoring through imaging and endoscopic exams. This paradigm shift reflects advancements in cancer treatment where precision monitoring enables organ preservation without compromising outcomes.

The Critical Role of Surveillance Adherence

Optimal surveillance forms the backbone of successful Watch and Wait management. National Comprehensive Cancer Network (NCCN) guidelines recommend specific monitoring schedules including digital rectal exams every 3-6 months, pelvic MRI every 3-6 months for the first 2 years, and complete colonoscopy within the first year. These protocols are engineered to detect regrowth during the critical window when salvage surgery remains most effective. Despite this clear framework, variations in real-world implementation have raised concerns about standardization across institutions.

Study Design and Patient Cohort

A multicenter retrospective analysis examined 53 rectal adenocarcinoma patients from 2021-2022 who achieved complete clinical response after neoadjuvant therapy (typically chemoradiation regimens like FOLFOX or CAPOX). Researchers defined optimal surveillance as completion of all required endoscopic and imaging examinations within protocol-specified timeframes during the monitoring period. Patient demographics, socioeconomic factors, and clinical variables were analyzed using Fisher exact tests and Mann-Whitney U tests to identify adherence predictors. Survival analysis employed the Kaplan-Meier method to map surveillance event timelines.

Key Findings on Surveillance Compliance

Of 53 patients studied, only 33 (62%) received guideline-concordant surveillance over a median follow-up of 17 months. Younger patients demonstrated significantly better adherence, with optimal surveillance recipients having a median age of 54 years versus 63 years in the suboptimal group. Strikingly, socioeconomic factors including insurance status and education level showed no correlation with compliance. The most prevalent gaps occurred in critical first-year milestones: 48% missed the initial endoscopic/imaging surveillance within 9 months, while 34% failed to complete their first full colonoscopy within 18 months. These early monitoring points are clinically significant as over 80% of regrowth occurs within the first 24 months.

Overcoming Adherence Barriers

The study identifies several modifiable barriers contributing to surveillance gaps. Patient-related factors include poor health literacy, transportation challenges, and anxiety about test results. System-level obstacles involve fragmented care coordination between oncology, gastroenterology, and radiology teams. The research highlights the need for structured transition pathways, patient navigation programs, and digital health tools such as app-based appointment reminders. As study co-author Dr. Etzioni notes: ‘Surveillance isn’t passive observation—it’s an active intervention requiring the same commitment as surgery or chemotherapy’.

Implications for Clinical Practice

These findings underscore the importance of standardizing surveillance protocols across institutions. Healthcare teams should prioritize patient education about the life-saving potential of early regrowth detection, emphasizing that missed appointments could eliminate the window for curative salvage surgery. Targeted interventions should include dedicated Watch and Wait coordinators, centralized scheduling systems, and streamlined communication between specialists. Institutions should also consider age-specific counseling approaches, as older patients may require additional support navigating complex surveillance schedules.

Conclusion and Future Directions

While Watch and Wait represents a significant advancement in rectal cancer management, this study reveals substantial adherence gaps affecting nearly 40% of patients. The first year remains the most vulnerable period, with colonoscopy compliance proving particularly challenging as endoscopic capacity limitations impact timeliness. Future research should evaluate bundled surveillance visits and telehealth alternatives to improve access. As nonoperative management expands globally, ensuring equitable access to guideline-concordant monitoring will determine the long-term success of this paradigm-changing approach.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Pembrolizumab Plus Chemotherapy for Cervical Cancer: Five-Year Exploratory Analysis from the KEYNOTE-826 Randomized Clinical TrialFive-year data from KEYNOTE-826 confirm pembrolizumab combined with chemotherapy as a durable, first-line treatment improving survival in persistent, recurrent, or metastatic cervical cancer without new safety concerns.Sep 15, 2026Reevaluating Colorectal Cancer Surveillance in Inflammatory Bowel Disease: The Role of Family History Beyond Early-Onset CasesA nationwide cohort study reveals that in IBD patients, colorectal cancer risk increases notably with multiple affected relatives, challenging current guidelines prioritizing early-onset family history for surveillance.Sep 6, 2026Cancer Biologics Utilization After Biosimilar Entry and Financial Implications For Payers and PatientsThis study examines the impact of biosimilar introduction on cancer biologics, highlighting reduced costs and market share for originator biologics, benefiting both payers and patients.Aug 29, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Patient Perceptions of Telehealth Use in Head and Neck Cancer Surveillance: A Qualitative Synthesis
This review synthesizes evidence on patients’ perceptions of telehealth for head and neck cancer surveillance, highlighting barriers, benefits, and the potential of hybrid models to improve acceptability post-treatment.
Aug 2, 2026
New EORTC Questionnaire Module for Vulvar Cancer Quality of Life Undergoes Successful Cross-Cultural Pre-TestingThe EORTC QLQ-VU34, a new disease-specific quality-of-life module for vulvar cancer patients, was developed and pre-tested across nine European countries, showing high relevance and applicability.Aug 18, 2026
Circulating Tumor DNA Outperforms Merkel Cell Polyomavirus Antibodies for Monitoring Recurrence in Merkel Cell CarcinomaA multicenter cohort study demonstrates that circulating tumor DNA (ctDNA) is more accurate than Merkel cell polyomavirus (MCPyV) antibody testing in detecting recurrence of Merkel cell carcinoma, improving patient surveillance and risk strJul 14, 2026